Toremifene

CAT: 0804-HY-B0005A-01Size: 10 mgDry Ice: NoHazardous: No
CAT#:0804-HY-B0005A-01Size:10 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Toremifene (Z-Toremifene) is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis. Toremifene also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.07 μM and 2.6 μM, respectively[1][2].
CAS Number
[89778-26-7]
Product Name Alternative
Z-Toremifene; NK 622 (free base) ; FC-1157a (free base)
UNSPSC
12352005
Hazard Statement
H301, H311, H331, H341
Target
Estrogen Receptor/ERR
Type
Reference compound
Related Pathways
Vitamin D Related/Nuclear Receptor
Applications
Cancer-programmed cell death
Field of Research
Cancer; Infection
Assay Protocol
https://www.medchemexpress.com/toremifene.html
Concentration
10mM
Purity
99.86
Solubility
DMSO : 62.5 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
ClCC/C(C1=CC=CC=C1)=C(C2=CC=C(OCCN(C)C)C=C2)\C3=CC=CC=C3
Molecular Formula
C26H28ClNO
Molecular Weight
405.96
Precautions
H301, H311, H331, H341
References & Citations
[1]Matthew R Smith, Selective Estrogen Receptor Modulators to Prevent Treatment-Related Osteoporosis.Rev Urol. 2005; 7 (Suppl 3) : S30-S35.|[2]Gauri J Sabnis, Luciana Macedo, Olga Goloubeva, Toremifene - Atamestane; Alone or In Combination: Predictions from the Preclinical Intratumoral Aromatase Model. J Steroid Biochem Mol Biol. 2008 January; 108 (1-2) : 1-7.|[3]Taneja SS, Morton R, Barnette G, Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene. J Clin Oncol. 2013 Feb 10;31 (5) :523-9.|[4]Laura Cooper, et al. Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors. J Med Chem. 2020 Sep 4.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Citation 01
BioRxiv. 2020 May.|J Pharm Biomed Anal. 2021 Feb 20:195:113870.|Patent. US11696914.|Res Sq. 2020 Dec 31:rs.3.rs-100914.|Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|J Med Chem. 2020 Oct 8;63 (19) :11085-11099.|Viruses. 2021 Jun 28;13 (7) :1255.

Alternative Products

CatalogName
TRC-T547513-1GToremifene
TRC-T547490-5MG(E)-Toremifene
290224-01Toremifene citrate
448026-01(E) -Toremifene
A15265-10Toremifene 10mg
A15265-25Toremifene 25mg
A15265-500Toremifene 500mg

Popular Products